AI assistant
Sending…
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017
May 15, 2017
29977_dirs_2017-05-15_954958a3-fc18-41c8-af8c-e795fdb15ebf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-05-12
Reporting Person: BROWN MICHAEL S (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-05-12 | Common Stock | M | 3000 | $177.82 | Acquired | 3000 | Direct |
| 2017-05-12 | Common Stock | S | 3000 | $450.0 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-05-12 | Non-Qualified Stock Option (right to buy) | $177.82 | M | 3000 | Disposed | 2023-01-02 | Common Stock (3000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 17349 | Indirect |
Footnotes
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
More from REGENERON PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 8
Major Shareholding Notification
2026
Apr 30
Interim / Quarterly Report
2026
Apr 29
Regulatory Filings
2026
Apr 29
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Regulatory Filings
2026
Apr 8
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3